AFC-HD AMS Life Science Co., Ltd. Reports Consolidated Earnings Results for the Third Quarter Ended May 2021
July 12, 2021 at 05:00 am EDT
Share
AFC-HD AMS Life Science Co., Ltd. reported consolidated earnings results for the third quarter ended May 2021. For the quarter, the company reported net sales of JPY 14,495 million compared to JPY 11,673 million a year ago. Operating profit was JPY 1,916 million compared to JPY 788 million a year ago. Profit attributable to owners of parent was JPY 1,359 million compared to JPY 441 million a year ago. Basic earnings per share was JPY 97.89 compared to JPY 31.42 a year ago. Diluted earnings per share was JPY 97.38 compared to nil a year ago.
AFC-HD AMS Life Science Co Ltd is a Japan-based company mainly engaged in the development of the healthcare business and the pharmaceutical business. The Company is engaged in the research and development, product design, manufacture and sale of health foods and cosmetics, manufacture and sale of Chinese medicine medicines, general medicines, generic medicines, healthcare products, the sale of natural foods, as well as planning of health information programs. The Company operates in two business segments. The Healthcare segment is engaged in the manufacture and sale of health foods and cosmetics, as well as the provision of original equipment manufacturers (OEM). The Pharmaceutical segment is engaged in the manufacture and sale of ethical drugs and over-the-counter drugs, as well as the sale of generic drugs. The Company is also engaged in the management of restaurants through subsidiary.
AFC-HD AMS LIFE SCIENCE CO., LTD. 
